FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

WuXi Biologics to Build Massive Vaccine Facility

May 30, 2019
A A

Chinese contract manufacturer WuXi Biologics entered into a $3 billion contract to build a huge vaccine manufacturing plant.

WuXi Vaccines, a venture company to be established with Shanghai-based Hile Biotechnology, will handle construction of the massive plant. The facility will manufacture “100 percent of the global market” of one of its partner’s vaccine products.

Chris Chen, CEO of WuXi Biologics, called vaccine contract manufacturing “one of the next growth areas” for the company.

View today's stories